1-(2-O-acetyl-3,5-di-O-benzoyl-β-L-xylo-furanosyl)uracil | 154463-66-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 1-(2-O-acetyl-3,5-di-O-benzoyl-β-L-xylo-furanosyl)uracil
• 英文别名: 1-(2-O-acetyl-3,5-di O-benzoyl-beta-L-xylofuranosyl)uracil；[(2S,3R,4S,5S)-4-acetyloxy-3-benzoyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl benzoate
• CAS: 154463-66-8
• 化学式: C₂₅H₂₂N₂O₉
• 分子量: 494.458
• InChiKey: FSLYMRHHQDGQAM-FKVLARQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  138
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  1-(2-O-acetyl-3,5-di-O-benzoyl-β-L-xylo-furanosyl)uracil 以68的产率得到1-(3,5-di-O-benzoyl-β-L-xylofuranosyl)-uracil
  参考文献：
  名称：

  &bgr;-L-2′-deoxy-nucleosides for the treatment of hepatitis B

  摘要：

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予一种抗HBV生物活性2'-脱氧-β-L-核糖核苷或其药学上可接受的盐或前药的有效量，其中2'-脱氧-β-L-核糖核苷的化学式为：其中R选自H、直链、支链或环烷基，CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单、二或三磷酸盐或磷酸衍生物；BASE是一种嘌呤或嘧啶碱基，可以选择性地被取代。2'-脱氧-β-L-核糖核苷或其药学上可接受的盐或前药可以单独或与另一种2'-脱氧-β-L-核糖核苷或另一种抗乙型肝炎药物联合给予。

  公开号：

  US06395716B1
• 作为产物：
  描述：

  2,4-二(三甲硅氧基)嘧啶 、 1,2-di-O-acetyl-3,5-di-O-benzoyl-L-xylofuranose 在 2,4-二(三甲硅氧基)嘧啶 作用下， 生成 1-(2-O-acetyl-3,5-di-O-benzoyl-β-L-xylo-furanosyl)uracil
  参考文献：
  名称：

  &bgr;-L-2′-deoxy-nucleosides for the treatment of hepatitis B

  摘要：

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予一种抗HBV生物活性2'-脱氧-β-L-核糖核苷或其药学上可接受的盐或前药的有效量，其中2'-脱氧-β-L-核糖核苷的化学式为：其中R选自H、直链、支链或环烷基，CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单、二或三磷酸盐或磷酸衍生物；BASE是一种嘌呤或嘧啶碱基，可以选择性地被取代。2'-脱氧-β-L-核糖核苷或其药学上可接受的盐或前药可以单独或与另一种2'-脱氧-β-L-核糖核苷或另一种抗乙型肝炎药物联合给予。

  公开号：

  US06395716B1

文献信息

• Synthesis and antiviral evaluation of β-L-<i>Xylo</i>-fuanosyl nucleosides of the five naturally occurring nucleic acid bases
  作者：Gilles Gosselin、Marie-Christine Bergogne、Jean-Louis Imbach

  DOI：10.1002/jhet.5570300510

  日期：1993.10

  The β-L-xylo-furanosyl analogues of the naturally occurring nucleosides have been synthesized and their antiviral properties examined. All these compounds were hitherto unknown and they were stereospecifically prepared by glycosylation of pyrimidine and purine aglycons with a suitably peracyl-L-xylo-furanose (specially synthesized from L-xylose for our present purpose), followed by removal of the protecting

  已经合成了天然存在的核苷的β-L-二甲苯基-呋喃糖基类似物，并研究了它们的抗病毒特性。迄今为止，所有这些化合物都是未知的，它们是通过嘧啶和嘌呤糖苷配基与合适的过酰基-L-木糖-呋喃糖（为达到我们目前的目的特别从L-木糖合成）进行糖基化立体定向制备的，然后除去保护基团。测试了所有制备的化合物对多种DNA和RNA病毒（包括HIV）的活性，但它们未显示出显着的抗病毒活性。
• Methods of treating hepatitis delta virus infection with beta-l-2'-deoxy-nucleosides
  申请人：——

  公开号：US20020035085A1

  公开（公告）日：2002-03-21

  A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof.

  一种治疗感染乙型肝炎的宿主的方法和组合物，包括给予所述2'-脱氧-β-L-赤霉糖核苷或其药用可接受的盐或前药的有效乙型肝炎治疗剂量。
• &bgr;-L-2'-deoxy-nucleosides for the treatment of hepatitis B
  申请人：Novirio Pharmaceuticals Limited

  公开号：US06444652B1

  公开（公告）日：2002-09-03

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予有效量的抗HBV生物活性2'-脱氧-β-L-核糖呋喃核苷或其药物可接受的盐或前药，其中2'-脱氧-β-L-核糖呋喃核苷的化学式为：其中R选自H、直链、支链或环烷基、CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单、二或三磷酸盐或磷酸衍生物；BASE是一种可以选择性取代的嘌呤或嘧啶碱基。2'-脱氧-β-L-核糖呋喃核苷或其药物可接受的盐或前药可以单独或与另一种2'-脱氧-β-L-核糖呋喃核苷或其他抗乙型肝炎药物联合使用。
• [EN] beta -L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B<br/>[FR] beta -L-2'-DESOXY-NUCLEOSIDES POUR LE TRAITEMENT DE L'HEPATITE B
  申请人：NORIVIO PHARMACEUTICALS LTD

  公开号：WO2000009531A2

  公开（公告）日：2000-02-24

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2'-deoxy-β-L-erythro-pentofuranonucleoside has formula (I) wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2'-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2'-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予有效量的抗HBV生物活性2'-脱氧-β-L-erythro-戊糖核苷或其药学上可接受的盐或前药，其中2'-脱氧-β-L-erythro-戊糖核苷具有式(I)，其中R选自H、直链、支链或环烷基、CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单磷酸、二磷酸或三磷酸或磷酸衍生物；而基团是一种可以选择性地被取代的嘌呤或嘧啶碱基。2'-脱氧-β-L-erythro-戊糖核苷或其药学上可接受的盐或前药可以单独给予或与另一种2'-脱氧-β-L-erythro-戊糖核苷或另一种抗乙型肝炎药物联合给予。
• 2' or 3' -deoxy and 2' , 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents
  申请人：Gosselin Gilles

  公开号：US20050101776A1

  公开（公告）日：2005-05-12

  Method for the sterospecific preparation of 2′ or 3′ deoxy and 2′,3′-dideoxy-β-L-pentafuranonucleoside compounds. 2′ or 3′ deoxy and 2′,3′-dideoxy-β-L-pentofuranonucleoside compounds are also described. Finally, the invention concerns the use of these compounds, and particularly 2′,3′dideoxy-β-L-fluorocytidine, as drugs, and especially as anti-viral agents.

  一种立体选择性制备2′或3′去氧和2′,3′-二去氧-β-L-戊糖核苷化合物的方法。还描述了2′或3′去氧和2′,3′-二去氧-β-L-戊糖核苷化合物。最后，本发明涉及这些化合物的用途，特别是2′,3′-二去氧-β-L-氟胞嘧啶作为药物，特别是作为抗病毒剂。